<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03865420</url>
  </required_header>
  <id_info>
    <org_study_id>AAAR7275</org_study_id>
    <nct_id>NCT03865420</nct_id>
  </id_info>
  <brief_title>Amyotrophic Lateral Sclerosis (ALS) Families Project</brief_title>
  <official_title>Amyotrophic Lateral Sclerosis (ALS) Families Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This program provides family members of individuals with familial ALS the opportunity to&#xD;
      contribute to research focused on learning more about why motor neuron degeneration begins&#xD;
      and how or why it progresses. This study provides genetic counseling and testing to help&#xD;
      participants understand and manage their risk and determine if they want to learn their&#xD;
      genetic status. This study will follow unaffected ALS gene mutation carriers on an annual&#xD;
      basis to gather essential information that will ultimately help researchers develop novel&#xD;
      therapies for the prevention and treatment of ALS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 10% of people with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's&#xD;
      Disease, have a family history of ALS or a related condition called frontotemporal dementia&#xD;
      (FTD). In most of these familial cases, and a significant number of &quot;sporadic&quot; patients with&#xD;
      no family history, a mutation is present in one of a growing number of genes that have been&#xD;
      associated with ALS and/or FTD.&#xD;
&#xD;
      The ALS Families Project will study unaffected carriers of ALS/FTD-associated gene mutations&#xD;
      to investigate the first steps in the disease process that leads to motor neuron&#xD;
      degeneration, with the goal of identifying early disease targets and points of intervention&#xD;
      to slow or stop disease onset and progression.&#xD;
&#xD;
      Unaffected individuals who have either a family member with a known ALS/FTD-associated gene&#xD;
      mutation or have a strong family history of ALS and FTD are invited to participate in the ALS&#xD;
      Families Project. For those who enroll, research visits will occur every 6-12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2018</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to emergence of symptoms attributable to gene mutations</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Emergence of symptoms will defined by the development of any of the following: a) any weakness on neurological examination, b) evidence of nerve loss on electromyography (EMG)-nerve conduction studies, or or c) evidence of cognitive impairment on the ALS-Cognitive Behavioral Scale (ALS-CBS).</description>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>ALS</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA, RNA, plasma, serum and Peripheral blood mononuclear cells (PBMCs)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Unaffected individuals who have either a family member with a known ALS/FTD-associated gene&#xD;
        mutation or have a strong family history of ALS and FTD.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women of any race or ethnicity aged 18 or older&#xD;
&#xD;
          -  No symptoms of ALS or fronto-temporal dementia at enrollment&#xD;
&#xD;
          -  Have a first degree relative who had an ALS-spectrum diagnosis with a confirmed&#xD;
             ALS-spectrum gene mutation; or already have had genetic testing and have tested&#xD;
             positive for an ALS-spectrum gene mutation.&#xD;
&#xD;
          -  Willing to undergo genetic testing with option of whether or not to learn results&#xD;
&#xD;
          -  Willing to travel to Columbia University Irving Medical Center (CUIMC) every 6-24&#xD;
             months for study procedures&#xD;
&#xD;
          -  Capable of providing informed consent and following study procedures, or has a legally&#xD;
             authorized representative who is able to consent for the subject.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known HIV&#xD;
&#xD;
          -  Known hepatitis B&#xD;
&#xD;
          -  Known hepatitis C&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>105 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Harms, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Harrington, MS, CGC</last_name>
    <phone>347-852-5315</phone>
    <email>ALSFamiliesProject@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthew Harms, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Harrington, MS, CGC</last_name>
      <phone>347-852-5315</phone>
      <email>ALSFamiliesProject@cumc.columbia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre-symptomatic</keyword>
  <keyword>Familial</keyword>
  <keyword>FALS</keyword>
  <keyword>Genetic testing</keyword>
  <keyword>C9orf72</keyword>
  <keyword>SOD1</keyword>
  <keyword>TARDBP</keyword>
  <keyword>FUS</keyword>
  <keyword>VCP</keyword>
  <keyword>PFN1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

